EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer
SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) — EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious journal “Clinical Cancer Research”, published by the American Association for Cancer Research.
The Carolyn Trial, named in honour of the first pancreatic cancer patient to receive the ANDC treatment, demonstrated significant improvements in patient outcomes compared to traditional chemotherapy.
This groundbreaking treatment utilizes Armed Nanocell Drug Conjugates (ANDCs) to deliver targeted therapy directly to cancer cells, while sparing healthy tissues from damage. The results of the trial have sparked hope for a more effective and less toxic treatment option for pancreatic cancer patients.
EnGeneIC’s ANDC technology represents a major advancement in the field of personalized cancer therapeutics, offering new possibilities for individualized treatment strategies. By harnessing the power of nanotechnology, this innovative approach holds great promise for improving outcomes and quality of life for cancer patients.
In conclusion, EnGeneIC’s groundbreaking ANDC treatment marks a significant milestone in the fight against pancreatic cancer and paves the way for a new era of personalized cancer therapy. This breakthrough has the potential to revolutionize cancer treatment and bring hope to patients worldwide.
How will this affect me?
As a potential future cancer patient, the development of EnGeneIC’s ANDC treatment offers hope for more effective and less toxic treatment options. This breakthrough represents a major advancement in personalized cancer therapy, providing the possibility of tailored treatments based on individual genetic profiles.
How will this affect the world?
EnGeneIC’s ANDC treatment has the potential to have a profound impact on cancer treatment worldwide. By offering targeted therapy that spares healthy tissues from damage, this breakthrough has the potential to improve patient outcomes and quality of life on a global scale. The development of personalized cancer therapeutics represents a significant step forward in the fight against cancer.
